7 December 2020 In a collaborative project between NICM Health Research Institute and Australian Natural Therapeutics Group (ANTG), researchers will start screening volunteers in 2021 for a two-year trial investigating the effects of a novel cannabis based-medicine on cognitive function in people with early-stage Alzheimer’s disease.
12 November 2020 A cross-sectional and longitudinal analysis of data from the UK Biobank, involving almost 85,000 people, has found that lifestyle factors such as less screen time, adequate sleep, a better-quality diet, and physical activity strongly impact depression. With evolving data exploring the link between depression and lifestyle factors, the international research team led by Western Sydney University say their findings published today in BMC Medicine may help inform public health policy.
NICM HRI 2021 Medicinal Cannabis Symposium brings together Australia’s leading medicinal cannabis researchers, academics and clinicians, showcasing current Australian research, and discussing regulatory developments and education regarding medicinal cannabis.
The clinical trial of SLT for vascular dementia is a multicentre study to evaluate the effectiveness and safety of a standardised herbal medicine formula in patients with vascular dementia and Alzheimer's disease with cerebrovascular disease (mixed dementia). Read more about SLT for Vascular Dementia